Logo image of XLO

XILIO THERAPEUTICS INC (XLO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:XLO - US98422T1007 - Common Stock

0.6618 USD
-0.01 (-1.08%)
Last: 12/22/2025, 4:30:02 PM
0.685 USD
+0.02 (+3.51%)
After Hours: 12/22/2025, 4:30:02 PM
Fundamental Rating

2

XLO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. While XLO seems to be doing ok healthwise, there are quite some concerns on its profitability. XLO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

XLO had negative earnings in the past year.
XLO had a negative operating cash flow in the past year.
In the past 5 years XLO always reported negative net income.
In the past 5 years XLO always reported negative operating cash flow.
XLO Yearly Net Income VS EBIT VS OCF VS FCFXLO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

XLO has a Return On Assets of -42.02%. This is comparable to the rest of the industry: XLO outperforms 57.36% of its industry peers.
With a Return On Equity value of -795.33%, XLO is not doing good in the industry: 79.62% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -42.02%
ROE -795.33%
ROIC N/A
ROA(3y)-90.24%
ROA(5y)-91.52%
ROE(3y)-207.32%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
XLO Yearly ROA, ROE, ROICXLO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200 400 600 800 1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for XLO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XLO Yearly Profit, Operating, Gross MarginsXLO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

More info and screens

5

2. Health

2.1 Basic Checks

XLO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for XLO has been increased compared to 1 year ago.
The number of shares outstanding for XLO has been increased compared to 5 years ago.
XLO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
XLO Yearly Shares OutstandingXLO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
XLO Yearly Total Debt VS Total AssetsXLO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -4.81, we must say that XLO is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.81, XLO is doing worse than 62.08% of the companies in the same industry.
XLO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.81
ROIC/WACCN/A
WACC8.53%
XLO Yearly LT Debt VS Equity VS FCFXLO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

XLO has a Current Ratio of 2.32. This indicates that XLO is financially healthy and has no problem in meeting its short term obligations.
XLO's Current ratio of 2.32 is on the low side compared to the rest of the industry. XLO is outperformed by 72.83% of its industry peers.
XLO has a Quick Ratio of 2.32. This indicates that XLO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.32, XLO is doing worse than 70.94% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.32
Quick Ratio 2.32
XLO Yearly Current Assets VS Current LiabilitesXLO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 68.26% over the past year.
EPS 1Y (TTM)68.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.27%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%742.51%

3.2 Future

Based on estimates for the next years, XLO will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.00% on average per year.
XLO is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -19.00% yearly.
EPS Next Y63.43%
EPS Next 2Y34.52%
EPS Next 3Y14.83%
EPS Next 5Y18%
Revenue Next Year462.46%
Revenue Next 2Y178.6%
Revenue Next 3Y22.54%
Revenue Next 5Y-19%

3.3 Evolution

XLO Yearly Revenue VS EstimatesXLO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M
XLO Yearly EPS VS EstimatesXLO Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

XLO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year XLO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XLO Price Earnings VS Forward Price EarningsXLO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XLO Per share dataXLO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4

4.3 Compensation for Growth

XLO's earnings are expected to grow with 14.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.52%
EPS Next 3Y14.83%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XLO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

XILIO THERAPEUTICS INC

NASDAQ:XLO (12/22/2025, 4:30:02 PM)

After market: 0.685 +0.02 (+3.51%)

0.6618

-0.01 (-1.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/bmo
Earnings (Next)03-09 2026-03-09/amc
Inst Owners21.72%
Inst Owner Change-13.5%
Ins Owners0.66%
Ins Owner Change0%
Market Cap34.74M
Revenue(TTM)6.34M
Net Income(TTM)-56.22M
Analysts83.33
Price Target2.04 (208.25%)
Short Float %23.23%
Short Ratio9.41
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-192.81%
Min EPS beat(2)-287.6%
Max EPS beat(2)-98.02%
EPS beat(4)2
Avg EPS beat(4)-91.33%
Min EPS beat(4)-287.6%
Max EPS beat(4)11.7%
EPS beat(8)4
Avg EPS beat(8)-100.06%
EPS beat(12)7
Avg EPS beat(12)-63.15%
EPS beat(16)9
Avg EPS beat(16)-122.29%
Revenue beat(2)0
Avg Revenue beat(2)-18.29%
Min Revenue beat(2)-34.07%
Max Revenue beat(2)-2.51%
Revenue beat(4)0
Avg Revenue beat(4)-29.24%
Min Revenue beat(4)-48.27%
Max Revenue beat(4)-2.51%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-3%
EPS NY rev (3m)-199.03%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)11.28%
Revenue NY rev (3m)11.28%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.32
P/FCF N/A
P/OCF N/A
P/B 4.92
P/tB 4.92
EV/EBITDA N/A
EPS(TTM)-0.55
EYN/A
EPS(NY)-0.24
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS0.29
BVpS0.13
TBVpS0.13
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -42.02%
ROE -795.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-90.24%
ROA(5y)-91.52%
ROE(3y)-207.32%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.81%
Cap/Sales 2.92%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.32
Quick Ratio 2.32
Altman-Z -4.81
F-Score6
WACC8.53%
ROIC/WACCN/A
Cap/Depr(3y)42.95%
Cap/Depr(5y)81.37%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.27%
EPS Next Y63.43%
EPS Next 2Y34.52%
EPS Next 3Y14.83%
EPS Next 5Y18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%742.51%
Revenue Next Year462.46%
Revenue Next 2Y178.6%
Revenue Next 3Y22.54%
Revenue Next 5Y-19%
EBIT growth 1Y15.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year94.76%
EBIT Next 3Y9.46%
EBIT Next 5Y12.01%
FCF growth 1Y83.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y83.33%
OCF growth 3YN/A
OCF growth 5YN/A

XILIO THERAPEUTICS INC / XLO FAQ

What is the ChartMill fundamental rating of XILIO THERAPEUTICS INC (XLO) stock?

ChartMill assigns a fundamental rating of 2 / 10 to XLO.


What is the valuation status for XLO stock?

ChartMill assigns a valuation rating of 0 / 10 to XILIO THERAPEUTICS INC (XLO). This can be considered as Overvalued.


Can you provide the profitability details for XILIO THERAPEUTICS INC?

XILIO THERAPEUTICS INC (XLO) has a profitability rating of 0 / 10.